Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03608579 · ClinicalTrials.gov registry record · Phase 1
Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA
A Phase 1 study of Osteoarthritis, Hip, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03608579: Active Phase 1 study of Osteoarthritis, Hip, sponsored by Mayo Clinic.
NCT03608579 is a Phase 1 study of Osteoarthritis, Hip that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 24 participants, below the 1,272-participant average among 20 other Osteoarthritis, Hip trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03608579, a Phase 1 study of Osteoarthritis, Hip, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Will injection(s) of autologous culture-expanded AMSCs be safe and efficacious for treatment of painful Hip OA, and if so, which dosing regimen is most effective?
Primary Outcome
Defined as any untoward or undesirable medical occurrence in the form of signs, symptoms, abnormal findings, or diseases that emerge or worsen relative to baseline (i.e., if present upon study entry) during the study regardless of causal relationship. Methods i. Spontaneous subject reports ii. Subject interview by study personnel iii. Clinical examination during face-to-face clinic follow-ups
Conditions Studied
Interventions
- DRUG Autologous Adipose Derived Mesenchymal Stromal Cells
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-11-05 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT03608579 still lists
NCT03608579 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,272-participant average among 20 other Osteoarthritis, Hip trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Osteoarthritis, Hip appearing as the primary indexed condition, and to 1 intervention - of which Autologous Adipose Derived Mesenchymal Stromal Cells is the first listed.
NCT03608579 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03608579 about?
NCT03608579 is a clinical study titled "Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA". Will injection(s) of autologous culture-expanded AMSCs be safe and efficacious for treatment of painful Hip OA, and if so, which dosing regimen is most effective?
What is the current status of trial NCT03608579?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-11-05. Estimated completion is 2026-12.
What conditions does trial NCT03608579 study?
This clinical trial studies the following conditions: Osteoarthritis, Hip.
What interventions are being tested in trial NCT03608579?
The interventions under investigation include: Autologous Adipose Derived Mesenchymal Stromal Cells (DRUG).
Who is sponsoring clinical trial NCT03608579?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03608579 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis, Hip
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03608579's enrollment target sits among peer trials
24 20th of 20 higher than 1 of 20 other Osteoarthritis, Hip trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis, Hip trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acetabular Shell Positioning Using Patient Specific Instruments
COMPLETED · Phase 1
-
To Assess the Patients' Ability to Self-Administer Fasinumab
COMPLETED · Phase 1
-
Safety and Effectiveness of the HIT Reverse HRS
RECRUITING · NA
-
Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee
RECRUITING
-
Non-invasive Evaluation of Upper and Lower Body Function With Showmotion
RECRUITING · NA
-
G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI